. Author manuscript; available in PMC: 2020 Dec 1.

Published in final edited form as: Semin Thromb Hemost. 2019 May 20;45(4):354–372. doi: 10.1055/s-0039-1688497

Table 3.

Hematopoietic malignancies

Study	Cancer/number	Test	Findings
Crowley et al, 2017¹³⁷	Multiple myeloma	TEG	↓ K and ↑α-angle after induction. Hypercoagulability markers directly proportional to myeloma burden.
Crowley et al, 2017¹³⁷	Patients: 16	TEG
Giaccherini et al, 2016⁴⁵	Myeloproliferative neoplasms Patients: 39	ROTEM	↓ CFT and ↑MCF. MCF values indicated lower platelet reactivity in MPN patients.
Gracheva et al, 2015¹³⁵	Multiple myeloma	TEG	Thrombin generation test and TEG parameters (R, K, and MA) reveal hypercoagulability in patients with multiple myeloma.
Gracheva et al, 2015¹³⁵	Patients: 20	TEG
Crowley et al, 2015¹³⁸	Myeloma/MGUS Patients: 24	TEG	No difference in TEG parameters between multiple myeloma and MGUS.
Ko et al, 2015¹³⁶	Acute lymphoblastic leukemia	TEG	↓ R and ↑MA during induction.
Ko et al, 2015¹³⁶	Patients: 80	TEG	↓ R and ↑MA during induction.
Akay et al, 2015¹⁴⁰	Hematologic malignancies	ROTEM	No difference in TEG parameters in low-dose or high-dose random or single-donor platelet transfusions.
Akay et al, 2015¹⁴⁰	Patients: 100	ROTEM
Flisberg et al, 2009¹³⁹	Thrombocytopenia due to hematologic malignancy	ROTEM	Platelet transfusion in patients with hematologic malignancies is associated with ↓ CFT and ↑MCF.
Flisberg et al, 2009¹³⁹	Patients: 20	ROTEM

Abbreviations: CFT, clot formation time; K, kinetics; MA, maximal amplitude; MCF, maximum clot firmness; MGUS, monoclonal gammopathy of undetermined significance; MPN, myeloproliferative neoplasm; R, reaction time; ROTEM, rotational thromboelastometry; TEG, thromboelastography.